MoneyWorks4Me

Windlas Biotech - Quaterly Results

08 Feb 2024 Evaluate
The sales moved up 35.51% to Rs. 1622.13 millions for the December 2023 quarter as compared to Rs. 1197.04 millions during the year-ago period.Profit for the quarter ended December 2023 rises by 64.32% to Rs. 150.98  millions from Rs. 91.88 millions.OP of the company witnessed a marginal growth to 235.01 millions from 161.11 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 1622.13 1197.04 35.51 4596.71 3723.70 23.44 5130.83 4659.30 10.12
Other Income 31.64 21.62 46.35 90.28 76.31 18.31 99.65 67.06 48.60
PBIDT 235.01 161.11 45.87 651.95 514.31 26.76 702.07 596.01 17.80
Interest 3.05 1.57 94.27 8.27 6.22 32.96 7.86 14.17 -44.53
PBDT 231.96 159.54 45.39 643.68 508.09 26.69 694.21 581.84 19.31
Depreciation 33.89 31.35 8.10 99.08 87.96 12.64 123.64 121.47 1.79
PBT 198.07 128.19 54.51 544.60 420.13 29.63 570.57 460.37 23.94
TAX 47.09 36.31 29.69 132.65 108.16 22.64 144.13 74.76 92.79
Deferred Tax 2.39 8.65 -72.37 4.42 6.75 -34.52 0.63 -26.57 -102.37
PAT 150.98 91.88 64.32 411.95 311.97 32.05 426.44 385.61 10.59
Equity 103.99 107.21 -3.00 103.99 108.97 -4.57 104.63 108.97 -3.98
PBIDTM(%) 14.49 13.46 7.64 14.18 13.81 2.69 13.68 12.79 6.97
Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..